Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Alligator Bioscience AB. (12/11/19). "Press Release: CFO Per-Olof Schrewelius Leaves Alligator Bioscience". Lund.

Organisation Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
Products Product mitazalimab (ADC-1013)
  Product 2 ATOR-1015 (Alligator Bioscience, bispecific CTLA-4 antibody)
Persons Person Schrewelius, Per-Olof (Alligator Bioscience 201609c–202003 CFO LEFT 3/20)
  Person 2 Norlén, Per (Alligator Bioscience 201606 CEO)
     


Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that CFO (Chief Financial Officer) Per-Olof Schrewelius leaves the company to become CFO of Nordic Waterproofing (Nasdaq Stockholm: NWG). Per-Olof Schrewelius was recruited to Alligator in connection with the IPO in the fall of 2016 and has been responsible for building up the finance function in accordance with Nasdaq Stockholm’s regulations.

“We have almost doubled our staffing since the IPO and I want to thank Per-Olof for his valuable efforts in building the organization and, importantly, a high-quality finance function. I have greatly appreciated our cooperation and will miss Per-Olof as a really good colleague and friend. I wish him the best of luck in his future endeavors”, said Per Norlén, CEO of Alligator Bioscience.

Per-Olof Schrewelius will officially leave his position on March 15, 2020. To ensure a well-planned and stable handover, Alligator will immediately initiate a process for the recruitment of new CFO.


For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com

The information was submitted for publication, through the agency of the contact persons set out above, at 5:30 p.m. CET on December 11, 2019.


About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes six lead clinical and preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees.

For more information, please visit http://www.alligatorbioscience.com.

   
Record changed: 2020-03-15

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Alligator Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top